|
Target Audience
Psychiatrists
Learning Objective
After discussing data related to impairments in academic performance, social
relationships, and driving behaviors, you will be able to evaluate the benefits
of ADHD treatment for adolescents. You will also be better able to tailor an
effective treatment strategy to meet the needs of your adolescent patients and
improve overall functional outcomes.
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
Veritas Institute for Medical Education, Inc. designates this educational
activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should
only claim credit commensurate with the extent of their participation in the
activity.
Financial Disclosure Statement
In accordance with the ACCME’s Standards for Commercial Support, all CME
providers are required to disclose to the activity audience the relevant
financial relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial relationship
if he or she has a financial relationship in any amount occurring in the last 12
months with a commercial interest whose products or services are discussed in
the CME activity content over which the individual has control.
Disclosures are as follows:
Jeffrey Newcorn, MD―Cephalon Inc, Cortex Pharmaceuticals Inc, Eli Lilly
and Company, Novartis Pharmaceuticals Corporation, Ortho-McNeil, Pfizer Inc,
Shire (grant/research support, speakers bureau, and/or consultant).
Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc,
Eli Lilly and Company, Janssen Pharmaceutica Products LP, National Institute of
Mental Health, National Institute on Drug Abuse, Neurosearch, Novartis
Pharmaceuticals Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research
support, speakers bureau, and/or consultant).
The staff of Veritas Institute for Medical Education, Inc. has
nothing to disclose.
Unlabeled Use Disclosure Statement
Participants are advised that this CME activity contains references to
unlabeled/unapproved/investigational uses of bupropion, modafinil, nicotinic
receptor agonists (ie, varenicline), and venlafaxine to treat ADHD.
Method of Participation
Listen to the prerecorded telesymposium and complete the Posttest and CME
Activity Evaluation form. You will receive your statement of credit immediately.
There is no certificate processing fee.
|
Managing ADHD Impairments in Adolescents
Transitioning to Adulthood
Jeffrey Newcorn, MD
Release Date: February 2007
Expiration Date: January 31, 2008
At the end of the audio presentation, you
will be given a passcode. Please
enter it in the space below to access the post-test, activity evaluation,
and request for credit form.
 |